Literature DB >> 11217926

Matrix metalloproteinases in human diabetic and nondiabetic vitreous.

M Jin1, K Kashiwagi, Y Iizuka, Y Tanaka, M Imai, S Tsukahara.   

Abstract

PURPOSE: To compare matrix metalloproteinase (MMP) activities in human vitreous samples from patients with diabetic retinopathy (DR) and other vitreoretinal diseases, and to investigate the factors influencing the MMP activities in human DR vitreous samples.
METHODS: Thirty-one diabetic and 17 nondiabetic vitreous samples (from nine patients with macular holes and eight patients with epiretinal membranes) were examined. Samples collected at the time of pars plana vitrectomy were subjected to substrate zymography to conduct a quantitative analysis of MMP activity. Immunoblotting against antihuman MMP-1, 2, and 9 was performed to identify MMP in vitreous samples. The effects of posterior vitreous detachment (PVD), vitreous hemorrhage, proliferative membrane, traction detachment, and cystoid macular edema on MMP activities were investigated.
RESULTS: All vitreous samples from both DR and non-DR patients showed a single band at the position of 72 kD, corresponding to MMP-2. Another band at 99 kD, corresponding to MMP-9, was detected significantly more often in DR samples than in non-DR samples: 45.2% and 0%, respectively (P = 0.0007). The number of samples showing a band from MMP-9 was significantly higher in partial PVD samples than in complete PVD samples: 66.7% and 15.4%, respectively (P = 0.001).
CONCLUSION: The results indicated that MMP-9 may be involved in DR and that partial PVD may be related to the MMP-9 activity in DR.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11217926     DOI: 10.1097/00006982-200102000-00005

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  31 in total

Review 1.  Targeting inflammation in diabetes: Newer therapeutic options.

Authors:  Neeraj Kumar Agrawal; Saket Kant
Journal:  World J Diabetes       Date:  2014-10-15

2.  Doxycycline blocks gastric ulcer by regulating matrix metalloproteinase-2 activity and oxidative stress.

Authors:  Laishram Pradeepkumar Singh; Amartya Mishra; Debjit Saha; Snehasikta Swarnakar
Journal:  World J Gastroenterol       Date:  2011-07-28       Impact factor: 5.742

3.  Role of matrix metalloproteinase-9 in the development of diabetic retinopathy and its regulation by H-Ras.

Authors:  Renu A Kowluru
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-03-10       Impact factor: 4.799

Review 4.  Metalloproteinases as mediators of inflammation and the eyes: molecular genetic underpinnings governing ocular pathophysiology.

Authors:  Mahavir Singh; Suresh C Tyagi
Journal:  Int J Ophthalmol       Date:  2017-08-18       Impact factor: 1.779

5.  Increased intravitreal angiopoietin-2 levels associated with rhegmatogenous retinal detachment.

Authors:  Sirpa Loukovaara; Kaisa Lehti; Alexandra Robciuc; Timo Pessi; Juha M Holopainen; Katri Koli; Ilkka Immonen; Jorma Keski-Oja
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-11-12       Impact factor: 3.117

6.  Matrix metalloproteinase-2 in the development of diabetic retinopathy and mitochondrial dysfunction.

Authors:  Ghulam Mohammad; Renu A Kowluru
Journal:  Lab Invest       Date:  2010-05-17       Impact factor: 5.662

7.  Interphotoreceptor retinoid-binding protein (IRBP) is downregulated at early stages of diabetic retinopathy.

Authors:  M Garcia-Ramírez; C Hernández; M Villarroel; F Canals; M A Alonso; R Fortuny; L Masmiquel; A Navarro; J García-Arumí; R Simó
Journal:  Diabetologia       Date:  2009-10-13       Impact factor: 10.122

8.  Oxidative stress and the development of diabetic retinopathy: contributory role of matrix metalloproteinase-2.

Authors:  Renu A Kowluru; Mamta Kanwar
Journal:  Free Radic Biol Med       Date:  2009-04-05       Impact factor: 7.376

9.  Matrix metalloproteinase-9 contributes to choroidal neovascularization.

Authors:  Vincent Lambert; Carine Munaut; Maud Jost; Agnès Noël; Zena Werb; Jean-Michel Foidart; Jean-Marie Rakic
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

10.  High intravitreal TGF-β1 and MMP-9 levels in eyes with retinal vein occlusion.

Authors:  R Tuuminen; S Loukovaara
Journal:  Eye (Lond)       Date:  2014-06-20       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.